1. IL2Cx alone or in combination with anti–CTLA-4 increases the CD8/Treg ratio in the tumor.
IL2Cx alone or in combination with anti–CTLA-4 increases the CD8/Treg ratio in the tumor. C57BL/6 mice harboring B16F10-OVA tumors were treated as described in Fig. 3A. Flow-cytometry analysis of tumor-infiltrating T cells was done 6 days after the beginning of the treatment. A, Representative dot plots of Foxp3 and CD4+ expression on CD45+ cells from the tumor and tumor-draining lymph nodes (dLN). Numbers indicate the frequency (%) of Tregs in the indicated gates. B, Frequency (%) of Tregs among CD45+ cells in the tumor (left) and in dLN (right) from A. C, Ratio of CD8+/Tregs in the tumor, calculated as frequency of total CD8+T cells among CD45+ cells/frequency of total Tregs among CD45+ cells. D, Quantification of CTLA-4 median fluorescence intensity (MFI) in the indicated TILs (left). Heat map of the MFI of CTLA4, CD25, ICOS, GITR, and PD-1 on Treg, Teff, and CD8+ T cells in the tumor and dLNs (right). Data are from three (A–C) or one (D) independent experiments. P values were calculated using one-way ANOVA and Kruskal–Wallis test. **, P < 0.01; ****, P < See also Supplementary Fig. S5.
Pamela Caudana et al. Cancer Immunol Res 2019;7:
©2019 by American Association for Cancer Research